FPX, a selective factor Xa inhibitor, produces a linear antithrombin-mediated effect and does not bind Platelet factor IV, thereby reducing the risk of over-anticoagulation and thrombocytopenia (Tantavisut et al., 2025; Gillette et al., 2013). Here, F10 is linked to Thrombocytopenia.